Home
Home

Orencia

Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China

Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
Yahoo

Can Bristol-Myers Squibb Compete In Immuno-Oncology?

Can Bristol-Myers Squibb Compete In Immuno-Oncology?
Seeking Alpha

This Blockbuster Drug Gets a Green Light

This Blockbuster Drug Gets a Green Light
Motley Fool

Bristol-Myers Squibb Zeroes In On A Blockbuster Cancer Drug

Bristol-Myers Squibb Zeroes In On A Blockbuster Cancer Drug
Seeking Alpha

U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis

U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA® (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Yahoo/BusinessWire

Bristol-Myers Arthritis Drug Fails to Win Backing of U.K. Agency

Bristol-Myers Arthritis Drug Fails to Win Backing of U.K. Agency
Bloomberg

News

Bristol-Myers Squibb: Outstanding Pipeline Makes It Most Attractive Among Large Pharmaceuticals
Seeking Alpha

News

Bristol-Myers' Orencia gets expanded use in Europe
Yahoo/AP
»

News

Will new label help Bristol's Orencia?
Fierce Pharma
»

News

Bristol-Myers' Orencia: Small Change, Big Impact?
Motley Fool
»